CLINICAL TRIALS PROFILE FOR MYFORTIC

505(b)(2) Clinical Trials for MYFORTIC

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00374803 ↗	Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal	Completed	Novartis	Phase 4	2006-04-01	To determine the safety and efficacy of a new formulation of Myfortic in combination with tacrolimus and thymoglobulin.
New Formulation	NCT00374803 ↗	Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal	Completed	University of Cincinnati	Phase 4	2006-04-01	To determine the safety and efficacy of a new formulation of Myfortic in combination with tacrolimus and thymoglobulin.
New Combination	NCT03249831 ↗	A Blood Stem Cell Transplant for Sickle Cell Disease	Recruiting	California Institute for Regenerative Medicine (CIRM)	Phase 1	2019-01-04	Blood stem cells can produce red blood cells (which carry oxygen), white blood cells of the immune system (which fight infections) and platelets (which help the blood clot). Patients with sickle cell disease produce abnormal red blood cells. A blood stem cell transplant from a donor is a treatment option for patients with severe sickle cell disease. The donor can be healthy or have the sickle cell trait. The blood stem cell transplant will be given to the patient as an intravenous infusion (IV). The donor blood stem cells will then make normal red blood cells - as well as other types of blood cells - in the patient. When blood cells from two people co-exist in the patient, this is called mixed chimerism. Most children are successfully treated with blood stem cells from a sibling (brother/sister) who completely shares their tissue type (full-matched donor). However, transplant is not an option for patients who (1) have serious medical problems, and/or (2) do not have a full-matched donor. Most patients will have a relative who shares half of their tissue type (e.g. parent, child, and brother/sister) and can be a donor (half-matched or haploidentical donor). Adult patients with severe sickle cell disease were successfully treated with a half-matched transplant in a clinical study. Researchers would like to make half-matched transplant an option for more patients by (1) improving transplant success and (2) reducing transplanted-related complications. This research transplant is being tested in this Pilot study for the first time. It is different from a standard transplant because: 1. Half-matched related donors will be used, and 2. A new combination of drugs (chemotherapy) that does not completely wipe out the bone marrow cells (non-myeloablative treatment) will be used to prepare the patient for transplant, and 3. Most of the donor CD4+ T cells (a type of immune cells) will be removed (depleted) before giving the blood stem cell transplant to the patient to improve transplant outcomes. It is hoped that the research transplant: 1. Will reverse sickle cell disease and improve patient quality of life, 2. Will reduce side effects and help the patient recover faster from the transplant, 3. Help the patient keep the transplant longer and 4. Reduce serious transplant-related complications.
New Combination	NCT03249831 ↗	A Blood Stem Cell Transplant for Sickle Cell Disease	Recruiting	City of Hope Medical Center	Phase 1	2019-01-04	Blood stem cells can produce red blood cells (which carry oxygen), white blood cells of the immune system (which fight infections) and platelets (which help the blood clot). Patients with sickle cell disease produce abnormal red blood cells. A blood stem cell transplant from a donor is a treatment option for patients with severe sickle cell disease. The donor can be healthy or have the sickle cell trait. The blood stem cell transplant will be given to the patient as an intravenous infusion (IV). The donor blood stem cells will then make normal red blood cells - as well as other types of blood cells - in the patient. When blood cells from two people co-exist in the patient, this is called mixed chimerism. Most children are successfully treated with blood stem cells from a sibling (brother/sister) who completely shares their tissue type (full-matched donor). However, transplant is not an option for patients who (1) have serious medical problems, and/or (2) do not have a full-matched donor. Most patients will have a relative who shares half of their tissue type (e.g. parent, child, and brother/sister) and can be a donor (half-matched or haploidentical donor). Adult patients with severe sickle cell disease were successfully treated with a half-matched transplant in a clinical study. Researchers would like to make half-matched transplant an option for more patients by (1) improving transplant success and (2) reducing transplanted-related complications. This research transplant is being tested in this Pilot study for the first time. It is different from a standard transplant because: 1. Half-matched related donors will be used, and 2. A new combination of drugs (chemotherapy) that does not completely wipe out the bone marrow cells (non-myeloablative treatment) will be used to prepare the patient for transplant, and 3. Most of the donor CD4+ T cells (a type of immune cells) will be removed (depleted) before giving the blood stem cell transplant to the patient to improve transplant outcomes. It is hoped that the research transplant: 1. Will reverse sickle cell disease and improve patient quality of life, 2. Will reduce side effects and help the patient recover faster from the transplant, 3. Help the patient keep the transplant longer and 4. Reduce serious transplant-related complications.

All Clinical Trials for MYFORTIC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00101738 ↗	Freedom Study: Myfortic in Kidney Transplant Patients	Completed	Novartis Pharmaceuticals	Phase 3	2003-03-01	The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.
NCT00149968 ↗	Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)	Completed	Novartis	Phase 4	2005-04-01	The purpose of this study is to assess whether a switch from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of renal transplant recipients who are experiencing any GI complaints under MMF-based immunosuppressive treatment.
NCT00154310 ↗	Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients	Completed	Novartis	Phase 4	2005-06-01	The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen containing enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine microemulsion, but results in better renal function.
NCT00167492 ↗	Enteric Coated Myfortic for Liver Transplant Recipients	Withdrawn	Novartis	Phase 4	2005-09-01	The purpose of this study is to replace the mycophenolate mofetil (Cellcept) which is our usual therapy after liver transplantation with sodium mycophenolic acid (Myfortic®) and to find out the effect this change may have on the development of side effects such as relief of gastrointestinal (stomach) problems. In the past we have had to stop Cellcept (our current drug) because of these side effects. We will also try to see if improved usage of this drug (Myfortic®) will allow us to use lower doses of other medications that lower your immune system. We will do some special tests on your blood to see if the amount of the drug is related with its effect on the immune system and side effects. Both Cellcept and Myfortic® are FDA approved medications although Myfortic® is not approved for use after liver transplantation. Myfortic® is really the same active drug as Cellcept® (Mycophenolic acid) but has been coated to prevent breakdown of the drug in the stomach and is made to lower the known gastrointestinal effects of Cellcept such as diarrhea, abdominal pain and nausea.

Clinical Trial Conditions for MYFORTIC

Condition Name

Condition Name for MYFORTIC
Intervention	Trials
Kidney Transplantation	21
Renal Transplantation	11
Liver Transplantation	6
Immunosuppression	6

Condition MeSH

Condition MeSH for MYFORTIC
Intervention	Trials
Kidney Failure, Chronic	9
Renal Insufficiency	8
Lymphoma, Non-Hodgkin	6
Lymphoma	6

Clinical Trial Locations for MYFORTIC

Trials by Country

Trials by Country for MYFORTIC
Location	Trials
United States	123
Germany	20
France	15
Canada	14
Spain	12

Trials by US State

Trials by US State for MYFORTIC
Location	Trials
California	14
Pennsylvania	13
New York	9
Florida	8
Wisconsin	7

Clinical Trial Progress for MYFORTIC

Clinical Trial Phase

Clinical Trial Phase for MYFORTIC
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	55
Phase 3	21

Clinical Trial Status

Clinical Trial Status for MYFORTIC
Clinical Trial Phase	Trials
Completed	64
Terminated	20
Unknown status	16

Clinical Trial Sponsors for MYFORTIC

Sponsor Name

Sponsor Name for MYFORTIC
Sponsor	Trials
Novartis Pharmaceuticals	35
Novartis	28
Sidney Kimmel Cancer Center at Thomas Jefferson University	5

Sponsor Type

Sponsor Type for MYFORTIC
Sponsor	Trials
Other	113
Industry	85
NIH	12

MYFORTIC Market Analysis and Financial Projection

Last updated: May 6, 2026

Myfortic (mycophenolic acid) Clinical Trials Update, Market Analysis, and Projections

What is Myfortic’s current clinical and regulatory status?

Myfortic is a delayed-release formulation of mycophenolic acid (MPA) used with cyclosporine and corticosteroids for prophylaxis of acute organ rejection in kidney transplant and for the treatment of active lupus nephritis in appropriate populations.

Key regulatory anchors

• US approval (NDA): Myfortic is approved for kidney transplant prophylaxis in adults and pediatric patients (age labeling varies by region and document version).
• US lupus nephritis indication: Myfortic is approved for treatment of active lupus nephritis in adult patients; use is in combination with other immunosuppressants per label language (commonly with background corticosteroids ± other agents).
• EU: Myfortic is approved for kidney transplant prophylaxis. EU lupus nephritis approval exists in label history, but the exact scope and wording depend on the regional product information.

Clinical activity as of the most recent publicly available registries

• Trial visibility for Myfortic itself is lower than for newer MPA competitors and combination strategies, because many studies now use mycophenolate (including generics) as background therapy.
• The most frequent clinical-trials pattern for Myfortic has been:
  • trials comparing exposure/PK and switching between formulations (delayed-release vs alternatives)
  • studies optimizing maintenance regimens and background therapy in transplant
  • lupus nephritis studies, often in combination with standard-of-care immunosuppression

Implication for “Myfortic trials update”

• The current high-value clinical signal is typically formulation and regimen optimization, not brand-new mechanism trials.
• Any near-term label-expansion thesis for Myfortic is constrained by the age of the active ingredient and by competing mycophenolate products and novel immunosuppressants.

Primary sources used for clinical and label structure

• US Prescribing Information for Myfortic (mechanism, indications, and boxed warnings) [1]
• EMA product information (where applicable for European labeling) [2]
• FDA label repository (documents and revisions) [3]

---

What clinical trial programs currently matter for MPA and Myfortic-related evidence?

Because the active ingredient is established, the operational “what matters” lens for investment and R&D is whether trials generate differentiation in:

• Efficacy endpoints (acute rejection rates, renal outcomes, flare rates in lupus nephritis)
• Safety endpoints (leukopenia, infection rates, GI intolerance)
• Exposure consistency (pharmacokinetic comparability; dose adherence and switching)
• Real-world regimen outcomes (persistence and discontinuation)

Where Myfortic has historically had evidence leverage

• Transplant prophylaxis: randomized and controlled evidence supporting delayed-release MPA in combination regimens.
• Lupus nephritis: clinical evidence supporting MPA-based immunosuppression strategies for renal flares and induction/maintenance phases depending on protocol.

How to interpret present-day trial pipelines

• The current trials that impact Myfortic’s market position tend to be:
  • comparative studies versus other mycophenolate forms, not versus biologics
  • regimen intensification or steroid-sparing strategies that still keep an MPA backbone
  • adherence and tolerability studies targeting GI side effects that drive discontinuation

This pattern matters because it determines whether outcomes improve for prescribers choosing between Myfortic vs other mycophenolate products.

---

How big is the Myfortic market today, by indication?

Myfortic competes primarily in two addressable segments:

1. Kidney transplant prophylaxis (large prevalence pool; high use of immunosuppressive backbones)
2. Lupus nephritis treatment (smaller patient pool; higher regimen management complexity)

Market structure reality

• In many markets, the mycophenolate ecosystem includes:
  • originator branded products (Myfortic)
  • generics and biosimilar-like competition for mycophenolic acid products (brand-to-generic substitution pressure)
  • alternative mycophenolate formulations (different release profiles)
• That shifts “market size” from pure demand growth to share-of-pocket and payer/coverage dynamics.

Commercial implication

• The brand’s revenue performance typically depends more on:
  • payer formulary position
  • therapeutic substitution policies
  • contracting and tendering for transplant formularies
  • acquisition cost differentials between brand and generic MPA

Evidence base for market sizing Public market sizing for Myfortic varies by vendor and methodology, but the directional model across analyses is consistent: steady demand in transplant, slower growth in lupus nephritis, and competitive pressure from generics.

Sources available for label and prescribing context

• USPI and labeling define the core approved use patterns and dosing constraints [1]
• EMA summaries confirm core indications and dosing context in Europe [2]

---

Who are Myfortic’s main competitors and what is the switching pressure?

Competition set

• Other mycophenolic acid or mycophenolate formulations (including generics)
• Alternative immunosuppressive backbones in transplant and lupus (not direct MPA substitutes in label language, but clinically competing regimens)

Switching pressure drivers

1. Generic entry and pricing
2. Formulary substitution rules
3. Tolerability and GI profile
4. Physician and transplant-center protocol standardization

Why Myfortic maintains relevance

• Delayed-release MPA can align with centers seeking a particular exposure profile and tolerability profile versus other formulations.
• In practice, switching often follows:
  • intolerance to one product
  • exposure targeting protocols
  • payer contracting changes

---

What does Myfortic’s patent and exclusivity landscape imply for revenue?

The Active ingredient is old, and Myfortic’s brand economics are usually dominated by:

• formulary churn to generics
• remaining exclusivity for formulation, method-of-use, or jurisdiction-specific data exclusivity
• any patent estates tied to specific crystalline forms, dosing regimens, or manufacturing processes (where applicable)

The operational revenue outlook assumes:

• continued share erosion where generic substitution is permitted without clinical justification
• price pressure in markets with multiple generic AMPs
• differential resilience where delayed-release formulations remain protocolized

Sources

• FDA and EMA labeling and document history support that the product is long established [1, 3]
• EMA product information and assessment artifacts provide the regulatory anchoring for EU presence [2]

---

What is the revenue projection for Myfortic over the next 3 to 7 years?

A defensible projection model for Myfortic must separate demand from share and price.

Projection framework (directional but operational)

• Transplant segment
  • Demand: largely stable, driven by transplant volumes and baseline immunosuppressive practice
  • Brand share: declines where generic mycophenolate is preferred unless delayed-release protocols are locked
  • Price: continues to compress; payer contracting determines net revenue trajectory
• Lupus nephritis segment
  • Demand: more variable due to patient selection, evolving standards, and competing immunosuppressive regimens
  • Brand share: affected by payer coverage and by whether clinicians keep MPA in induction and maintenance
  • Price: lower growth and increased substitution risk versus transplant

Base case directional projection (brand trajectory)

• Near-term (1-2 years): modest revenue stability or gradual decline driven by ongoing generic pressure and formulary position
• Mid-term (3-5 years): sharper share erosion where additional generic penetration or improved substitution rules expand
• Longer-term (5-7 years): continued decline to a plateau if delayed-release protocols and tolerability-driven prescribing persist in certain centers

What to use as decision thresholds

• If net price declines faster than share, revenue declines accelerate.
• If payer restrictions on brand substitution tighten for specific clinical rationales, revenue decline slows.
• If competing regimens shift away from MPA backbones, lupus nephritis contribution compresses disproportionately.

Projections cannot be stated as precise dollar figures without a specific market-research dataset and an auditable series. The operational forecast should be tied to your internal:

• current brand net price by geography and channel
• formulary coverage changes
• generic penetration timelines and contract expirations
• transplant-center adoption rates for delayed-release MPA

---

Key strategic implications for investors and R&D planners

1. Myfortic’s clinical differentiation is largely “process and tolerability/exposure” rather than new disease mechanisms.
   This makes competitive response primarily payer- and protocol-driven.
2. The biggest levers are formulary access and switching barriers, not trial novelty.
   Any new evidence must show measurable differences in clinically meaningful outcomes or adherence/persistence.
3. For pipeline work, trials must be designed to generate actionability (dose equivalence protocols, tolerability outcomes, renal endpoints in lupus subgroups, and transplant rejection endpoints).

---

Key Takeaways

• Myfortic remains a delayed-release mycophenolic acid option with established roles in kidney transplant prophylaxis and lupus nephritis per label. [1, 2]
• Current clinical-trial activity is more likely to support formulation, switching, PK/exposure consistency, tolerability, and regimen optimization than to generate brand-new mechanism differentiation.
• Market outlook is dominated by generic substitution and payer contracting; revenue direction is more sensitive to net price and formulary share than to incremental growth in underlying disease incidence.
• A credible projection approach separates transplant stability from brand erosion and treats lupus nephritis as a smaller but more substitution-sensitive contributor.

---

FAQs

1) Is Myfortic still a relevant therapy in kidney transplantation?

Yes. Myfortic remains indicated for kidney transplant rejection prophylaxis in combination immunosuppressive regimens per the US label. [1]

2) What drives Myfortic performance versus other mycophenolate products?

Net performance is driven by payer contracting, formulary preference for delayed-release formulations, and tolerability-linked adherence, since generics place sustained pricing pressure.

3) What clinical endpoints most matter for maintaining Myfortic’s differentiation?

Rejection rates in transplant, renal outcomes and flare control in lupus nephritis, and safety endpoints tied to discontinuation risk (GI intolerance, leukopenia) are the most decision-relevant.

4) How does generic competition affect Myfortic’s revenue outlook?

Generic mycophenolate products typically pressure brand net price and share; the brand’s resilience depends on protocolized delayed-release use and formulary restrictions tied to clinical rationale.

5) What is the highest-value evidence type for Myfortic in the next few years?

Comparative real-world and randomized evidence that demonstrates actionable differences in tolerability, exposure consistency, switching outcomes, and maintenance persistence within standard-of-care regimens.

---

References

[1] Food and Drug Administration. Myfortic (mycophenolic acid) prescribing information. FDA Label.
[2] European Medicines Agency. Myfortic product information (summary of product characteristics). EMA.
[3] U.S. FDA. Drug Approval Reports and label documentation for Myfortic (FDA repositories and label history).